Format

Send to

Choose Destination
Swiss Med Wkly. 2006 Nov 11;136(45-46):739-42.

Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

Author information

1
Department of Internal Medicine, University Hospital, Zurich, Switzerland. alexander.imhof@usz.ch

Abstract

BACKGROUND:

Voriconazole shows a considerable interpatient variation of serum concentrations.

METHODS AND RESULT:

In an analysis of 28 treatment courses, 6 patients presented with neurological adverse events (hallucination, encephalopathy, and visual disturbance). The hazard ratio per 0.1 mg/mL voriconazole serum level (sVL) increase was 2.27 (95% CI: 1.45-3.56, p <0.001). There was no correlation between sVL and creatinine (r = 0.12, p = 0.114), ALT (r = -0.14, p = 0.072), AST (r = 0.003, p = 0.964), alkaline phosphatase (r = 0.03, p = 0.723).

CONCLUSIONS:

Our findings demonstrate that elevated sVL is associated with neurological adverse events, and measurement of its serum concentration could improve voriconazole treatment and safety.

PMID:
17183438
DOI:
2006/45/smw-11547
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center